COVID-19 and Cancer Consortium study highlights racial disparities, increased mortality for patients facing dual diagnoses
Mar. 19, 2021—The COVID-19 and Cancer Consortium (CCC19) published new findings in the Annals of Oncology showing heightened mortality and racial disparities for patients with cancer diagnosed with SARS-CoV-2 infection.
Jun. 24, 2020—People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
Jun. 24, 2020—The Vanderbilt Dayani Center for Health and Wellness is now offering exercise planning consultations for people with cancer diagnoses.
TERAVOLT registry tracks outcomes of treatments among people with thoracic cancers sickened by COVID-19
Jun. 12, 2020—New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
Jun. 4, 2020—A month before his 49th birthday, Geoffrey Fleming, MD, had a biopsy of his liver to diagnose an unidentified metastatic disease that he already knew was “something bad.”
May. 28, 2020—People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.